International Life Sciences Awards 2022

International Life Sciences Awards 2022 Suenos Advisors: Medicine Strategist of the Year - Switzerland Research | Innovation | Consulting We support the Sustainable Development Goals

Drawing together scientific leaders across the Human, Animal, and Plant Life sectors, the International Life Sciences Awards 2022 are here to recognise the vital work and impressive talent which drives the industry and grows more abundant each year. Now more than ever we wish to support the efforts of an industry so crucial to our understanding of disease and the preservation of the environment around us. International Life Sciences Awards 2022 Sif Brookes, Senior Editor Website: AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.

Contents 4. Shigadry With Earth Co.: Best Healthcare Development & Research Specialists - East Asia 6. Suenos Advisors: Medicine Strategist of the Year - Switzerland 8. Esculape GmbH: Best Clinical Data Management Solutions Provider - Western Europe 9. Maritech® organic fucoidan: Most Innovative Ingredient 2022 (Australasia) 10. Life Science Success: Most Engaging Life Science Podcast - USA 11. TetraSOD®: TetraSOD®, a unique marine ingredient 12. Genomnis SA: Leading Pioneers in Genetic Bioinformatics 2022 13. KAHLITY GmbH: Best Pharmaceutical & Medical Device Consultancy - Northwest Switzerland 14. ISCA: Best Cosmetic Chemical Manufacturer 2022 15. Umami Meats: Best Aquaculture Company - Asia 16. iRhythm Technologies Ltd: Best Ambulatory Cardiac Monitoring Solution 2022: Zio® by iRhythm 17. Azzur Group LLC: Most Innovative Early-Phase Biotech Manufacturing Solutions Provider 2022 4. Cannamedical: Best Medical Cannabis Products Supplier 2022 - Germany

4 With a history dating back to 1966, the Shigadry Group of Japan is a leading technology research and innovations specialist developing products for the healthcare sector and for advancing clean environment management practices. Operating on a three-tier charter which ensures focused efforts for the improvement of the quality of life of the world’s population, the Group has developed a long-standing reputation as a specialist in medical and healthcare sectors. Research and development are the backbone of Shigadry’s business module. Our experts and scientists continuously develop new methodologies and processors which keeps us abreast of competition. We have long term associations with many leading Universities in Japan and all our products are tested at state of the art microbiology labs also based in Japan. Research domains- Infection control, Body weight distribution and pressure ulcer prevention and Climate change and carbon management. First in the world concepts- MRSA reduction certified hospital mattress(Patented), Nonalcoholic multipurpose antimicrobial(Patented) and Carbon negative product (US copyrights reserved) 2022’s Most Innovative Medical Aesthetic & Plastic Surgery Clinic - London Breaking Down the Barrier Between Eastern and Western Aesthetic Treatments Jul22102 Shigadry With Earth Co.: Best Healthcare Development & Research Specialists - East Asia • Anti-bacterial effect • Deodorizing effect • • Self contouring • Low interface pressure • Stain resistant All our products are manufactured to the highest quality standards aligned to the Japanese Industrial Standard (JIS) • Allergy free • Comba • 100% Water Resistant • Mold, dust, dust mites, bed b • Anti-permeability to b blood and urine Hygiene | Comfort | Safety TM Absolute Health Care Mattress PatentedMiracle Surface Technology Carbon Negative product FLAGSHIP PRODUCT Trusted and used by 1,600 hospitals all over Japan

GHP International Life Sciences Awards 2022 Sustainability- Shigadry with Earth Co. has developed a range of Industry leading Products and Concepts with Sustainability at Heart. Shigadry’s efforts are exemplary since Sustainable Innovation is embedded in the core of our Product strategy whilst maintaining industry leadership in value contribution. Our research, testing and verification ensures maximum use of Natural materials and minimum impact to the Environment throughout the Product Life Cycle(LCA). The results have been outstanding and outweighs by far most of its competition. We are proud to say that we are amongst one of the few Companies in the World that can directly correlate its Products with Specific Sustainable Development Goals (SDG) and are even more enthused to mention the fact that these are trend setters towards a Global Trading model that is truly Sustainable. The use of Shigady With Earth’s range of Products not only enhances Corporate Stewardship but greatly enhances the National Commitments on Sustainable Development Goals (SDGs) in the respective markets. Unique and sleek design with no seams, edges and threading ats MRSA Guaranteed 99.9995% hygiene and infection control • • • Uses a Patented Miracle Surface Technology bugs free bacteria, pus and humor, Superflex is entered in the ARTG, 316892 (Australian Register of Therapeutic Goods) Company : Shigadry With Earth Contact : [email protected] Website : Hidehiko Tanaka President Naushad MohideenHead, Global Business

6 structures that maintain them. Starting out at the renowned Merck Serono, he was proud to head up the establishment of Merck Oncology, building a complete clinical asset portfolio including the successful in-licensing of Erbitux, now valued at over $3bn annually. From here, Dr. Rohmann became the Managing Partner of Nextech Venture in Switzerland, raising two funds that returned more than eight times their original values to the original investors. After 10 years Dr. Rohmann moved to become Venture Capital Fund Manager for a Novartis PharmaAG – MPM Capital fund ($0.55bn), and gained board experience at many SMEs across Europe, US and Canada. Having climbed the professional ladder, Dr. Rohmann’s career led him to become founding CEO of Ganymed Pharmaceuticals together with Oezlem Tuereci and Ugur Sahin, which was eventually sold to Astellas in 2016. This team was in charge of establishing Biontech, which became best known for its injectable mRNA Covid-19 vaccine. Recently, Dr. Rohmann has been collaborating with colleagues from the Karolinska Institutet in the development of a nasal inhaled vaccine for Covid-19. This new company has also begun work on vaccines for HIV and influenza and tuberculosis. All of these viruses have unique challenges, but can be fought in the same way. Both efficacious and swift to act, these solutions can have already an impact in a few hours instead of days! Since these roles, however, Dr. Rohmann has focused on ensuring that Suenos Advisors has the strength and flexibility to thrive in the rapidly changing world of Life Science. He has built a business which embraces people who have unique qualities and competences, giving a diverse set of perspectives to any challenges that might arise. The ability of the company to look at assets and companies from a host of different viewpoints including the financing needs has been the key which has ensured that the team has remained so unique and competitive within the marketplace. Looking to the future, Dr. Rohmann has taken an approach which embraces the holistic. He has looked into the history of medicine to How does medicine move forward? Progress is not simply a matter of scientific development, but a complex network of checks and balances that consider the market as well as the benefit to humanity as a whole. Dr. Sven Rohmann of Suenos Advisors is a leader in the field, recognised in the International Life Sciences Awards 2022 from GHP. We thought it time to take a closer look at the direction of his career and the secrets of his success. The world of biotechnology is one brimming with potential. There is so much that could be done, if the right resources – financial and medical – were directed correctly. No one understands this better than Dr. Rohmann, who has spent his career finding ways of fulfilling potential. With years of expertise under his belt, Dr. Rohmann founded Suenos Advisors Est. in 2016 and has gone on to achieve overwhelming success as a result. Suenos Advisors was specifically designed to work alongside the cutting-edge of the biotechnology industry, focusing on the fields of immunology, oncology, auto-immune diseases and vaccines. Since opening its doors, Suenos Advisors has taken an active role in the running of numerous organisations in the medical sector, including serving as CEO and/or member of the board of public companies such as Helix Pharmaceutical Corp., Oasmia Pharmaceutical AB and Immunicum AB. Immunology has proven to be the foundation of most cutting-edge therapeutic and diagnostic approaches, supporting not only those companies which have been fighting Covid-19, but those which are tackling other diseases. The Life Science sector in which the Suenos Advisors team specialise has never been more vibrant and this has allowed the team to expand rapidly indeed. Currently, they have partners in Germany, Spain, Greece, Singapore and the USA, allowing them incredible access to the newest treatments that are being developed around the world. This growth has been guided by the capable leadership of Dr. Rohmann. His unique mix of skills, drawing on scientific, pharma/ biotech and venture knowledge as well as an impressive network of contacts in both the medical and financial sectors, has made him one of the world’s leading experts in innovation management as well as value building & capturing. Dr. Rohmann’s incredible skill has been allowed to flourish over the years thanks to working within structures that have provided him with footholds not only in the medical industry, but in the financial Worldwide Skincare Excellence “Suenos Advisors was specifically designed to work alongside the cutting-edge of the biotechnology industry, focusing on the fields of immunology, oncology, autoimmune diseases and vaccines.” Medicine Strategist of the Y ar - Switzerland

GHP International Life Sciences Awards 2022 uncover some of the ways in which ancient cultures tired to combat illnesses. Putting our modern knowledge into the context of these medical pioneers showcases that they were trying to achieve an immune health status. The lessons of the past that Dr. Rohmann has taken away is an awareness of the strong connection between the mind and body. To meet the new challenges facing us, and the looming mental health crisis, Dr. Rohmann has started Apollon Health Advisors in Greece. This incredible new venture is designed to promote the connection between a healthy mind and a healthy body. For too long, we have seen these two parts of ourselves as separate, but the time has come to take a holistic view of our health. Doing so is a sure-fire way of having the largest positive impact on our futures. To Dr. Rohmann, health is a topic which is becoming more and more important by the day. His exploration of the impact of the latest biotechnologies have not just flourished as a result of the medical developments, but thanks to the methods he has adopted in terms of investment. His achievements in this field are not over yet, as he pushes into bold new territory that combines the ideas of the past with the methods of tomorrow. The challenges of the pandemic have not only demonstrated that soon more effective vaccines and rapid diagnostic will be needed in the future, but that people genuinely value the quality of their health. Combined with the most recent breakthroughs in this topic with regards to digital health and artificial intelligence, it’s little wonder that he sees enormous potential in the spaces where many are not looking. It’s in these spaces, that often seem small, that the biggest of impacts can be made. Company: Suenos Advisors Name: Dr. Sven Rohmann

8 GHP International Life Sciences Awards 2022 Esculape GmbH provides all the services needed to ensure a safe, successful, and smooth-running clinical trial. Fromclinical data management solutions to data management oversight, the company has streamline solutions that can be delivered promptly and without a hitch. Based in Gladenbach, Hesse, Esculape GmbH are a specialised service provider in the field of clinical data management. For many years, Esculape has successfully worked with clients from the pharmaceutical industry, with medical researchers, and with external contract research organisations. The company’s main purpose encompasses independent data management, which it does with a comprehensive understanding of data and the outcome of the study. For instance, Esculape assist with the selection of CROs, research setup, and manage the data integrity and quality in a study from start to finish. The company offers a wide range of services – clinical data management, data management oversight, lead/project data management, privacy in clinical trials, and data management training courses. Of course, Esculape is best known for its clinical data management services, which sees the company prioritise data integrity. Indeed, Escualpe takes care of all relevant topics at an early stage, meaning that those running the clinical trial can focus on the most important elements. Esculape is enthusiastic about acting as a partner, no matter whether the client is a pharmaceutical firm in need of assistance with CRO selection, a clinician searching for professional guidance, or a CRO in need of help with order peaks. Henceforth, it is imperative that Esculape is supported by a highly professional and experienced team. Their vibrant backgrounds include an abundance of knowledge surrounding the field, and Esculape uses this to its advantage. As such, the team are expected to work to the best of their ability, always upholding the company’s mission and ethos, in order to provide its clients with an exceptional service. Collaboration, transparency, and trust are all key themes within the team’s success. Founded in 2015, the past seven years have been a whirlwind for the clinical data management solutions provider. The past few years are now represented by a number of memories marked by success. However, these trends are expected to continue going forward, as 2022 and 2023 are being filled with a plethora of exciting events and opportunities. One such example is that of 2023’s ACDM23 Conference in Barcelona, where Esculape will be participating as an exhibitor. Contact: Marina Mangold Company: Esculape GmbH Web Address: Best Clinical Data Management Solutions Provider - Western Europe Jun22310

9 GHP International Life Sciences Awards 2022 Australian biotechnology leader Marinova Pty Ltd is making waves in global healthcare. Its unique portfolio of bioactive seaweed extracts is the result of two decades of innovative R&D. Maritech® organic fucoidan represents the future of natural and sustainably sourced ingredients with proven efficacy. Most Innovative Ingredient 2022 (Australasia) arinova is dedicated to the development and production of high purity seaweed extracts for the betterment of human health. The company specialises in the research, development and manufacture of fucoidan compounds – highly bioactive polysaccharides derived from select species of brown seaweed. Sustainably sourced and clinically validated, Maritech® organic fucoidans are high purity seaweed extracts sought after by some of the world’s most trusted healthcare brands. They are included as premium ingredients in market-leading nutritional supplements, medical devices, functional foods and beverages, skincare and dermatological formulations, and animal health products. Company CEO, Mr Paul Garrott, explains, “There is rapidly growing interest in marine bioproducts and for good very reason. Superior ingredients in this category tick all the boxes – they are natural, sustainably sourced, supported by an extensive dossier of scientific evidence and have global regulatory acceptance. Maritech® organic fucoidans represent all this and more. They are ideal for new product innovators seeking novel ingredients with a clear point of differentiation.” “Maritech® fucoidan extracts are included in dietary supplements that target a diverse range of human health conditions. Immune support, gut and digestive health, and healthy ageing are key focus areas,” said Garrott. “Marinova is continually investing in rigorous scientific research including comprehensive in vitro investigations, animal studies and human clinical trials. The company is a partner in Australia’s Marine Bioproducts CRC – a dynamic consortium 70 partners involved in a $270 million dollar R&D program. Australia is very serious about the future for high quality marine bioproducts.” As the global leader in fucoidan science, Marinova is also the supplier of choice to world-renowned research institutions. “Our highly characterised fucoidan fractions are well-suited to medical device applications and pharmaceutical research,” explained Garrott. “Marinova also possesses the unique ability to isolate distinct fucoidan compounds with enhanced efficacy and superior compatibility with other biomaterials and therapeutic agents. Marinova is at the forefront of developing discrete fucoidans for medical research. The company’s team of scientists understand the unique physicochemical properties of fucoidan extracts and how these may be tailored to influence uptake and achieve targeted therapeutic effects.” Maritech® fucoidan is the world’s only high purity, certified organic fucoidan with global regulatory acceptance. “This is by virtue of our proprietary Maritech® extraction process,” explained Garrott. “Fucoidans have traditionally been precipitated from crude extracts using solvents. This may lead to contaminants being present in the final extract. Fucoidans manufactured in this way can suffer from many shortfalls. Their quality can be inconsistent, their chemical integrity may be compromised and – most importantly – their bioactivity may be affected.” The Maritech® extraction technology, developed and used exclusively by Marinova, overcomes these problems. Unique ‘green chemistry’ processes avoid organic solvents and produces fucoidan extracts that remain unadulterated in chemical structure and free from solvent residues. The mild, aqueous process also ensures the resulting extracts comply with the most rigorous quality standards and regulatory requirements. Marinova’s core fucoidan ingredients are extracted from two species of seaweed, Undaria pinnatifida (wakame) and Fucus vesiculosus (bladderwrack). “Fucoidans from these two species have been the most widely researched,” said Garrott. “They are also rapidly renewable marine resources that we are able to hand harvest – sustainably and ethically. In fact, the entire process from harvest through to the capture and reuse of waste places us on the cusp of being a genuine zero-waste operation. Importantly, our Maritech® extracts are the only certified organic, high purity fucoidan ingredients with global regulatory acceptance.” The future of Maritech® organic fucoidans is bright. “We are currently scaling up both our research investment and our production capacity here in Australia,” finished Garrott. “There are not many natural, bioactive ingredients that are supported by this volume of scientific evidence and demand for high purity fucoidan is rising significantly. We have some exciting research collaborations underway across the globe that have the potential to reshape human health and that’s rewarding indeed.” Company: Marinova Pty Ltd Email: [email protected] Website: M Dec21724 Maritech® organic fucoidan

10 GHP International Life Sciences Awards 2022 Life Science Success is a ground-breaking podcast that covers all the important topics in the life science arena. With the help of industry-leading guests, Don Davis explores the current state of the industry, innovative businesses, and where life sciences are heading. Most Engaging Life Science Podcast - USA podcast is a great way of spreading a message and reaching a niche audience. Reuters Institute’s Digital News Report 2022 suggests that over 34% of survey participants across 20 countries had listened to a podcast in the month preceding the survey. Indeed, podcasts are quickly becoming one of the key ways that people consume media, and therefore they can be exceptional tools for brands, businesses, or even entire industries. Within the Life Science industry, a fledgling podcast is beginning to take flight. Life Science Success covers a plethora of topics within the sector and features interviews with key industry players – so far, the podcast has conducted over 100 interviews. Released on a weekly basis, the podcast covers the guest’s proven methods, principles, strategies, and mindsets in order to implement new technologies that offer tangible benefits. ‘The podcast is differentiated from other podcasts in the space because we focus on the people and what they are doing to have an impact in our world,’ explains Don Davis, the host of Life Science Success. Don, who serves as the president and principal of 5280 Life Sciences Consulting, boasts over 30 years of experience working as an operations expert within both the healthcare and life science industries. Alongside leading the podcast, he also helps organisations bolster their quality processes, program and project management, analytics & KPIs, as well as IT systems and infrastructure in healthcare, medical devices and pharmaceuticals. As such, Don’s knowledge and passion for the industry means that Life Science Success is filled with challenging, compelling, and engaging content. ‘The life science podcast environment is a very interesting space,’ he adds. ‘There are podcasts that are hosted by vendors and individuals.’ Life Science Success began as a passion project for Don, in which he focusses primarily upon small to medium sized businesses in life sciences. The ongoing downturn in the United States economy is having an impact on those aforementioned companies; however, Don remains hopeful that, in spite of the challenges they’re facing, such businesses will continue to thrive and innovate. For Life Science Success, recent times have brought forth several exciting opportunities. At the Bio International Convention 2022 in San Diego, the podcast served as the media partner for the Music Beats Cancer Reception. The event fostered an environment in which those working on tackling cancer could come together, in a positive and vibrant environment, to network and share ideas. Moreover, within the next couple of months, Life Science Success will be celebrating the 100th episode of the podcast. Don has several plans for the future, including the release of a book - Overcommitted: How to Transform Your Habits and Achieve the Life You Desire will be available from the 30th of September. He will also be hosting another podcast, this time focusing on healthy eating. Be Fused will focus on the food people choose to put in their bodies and how it has the power to hurt or heal. Countless studies have shown that high fat, processed, and sugary foods increase the risk for certain diseases while eating a diet rich in whole grains and vegetables can safeguard against disease. Be Fused plans to raise awareness surrounding these foods and their impact. Contact: Don Davis Company: Life Science Success Web Address: A Jul22062

11 GHP International Life Sciences Awards 2022 As an extended follow-up of this first study, a new trial conducted with good fitness university students revealed that TetraSOD® supplementation induced favorable changes not only on anthropometric and hematological but also on hormonal levels. By the other side, additional clinical trials in trained subjects showed the capacity of TetraSOD®: i) to improve recovery, to sustain power, and to prevent declines in strength across repeated endurance and cross-training bouts, and to reduce muscle damage, ii) to improve perceptual and functional indices of exercise recovery in individuals following a non-functional overreaching resistance-training programme, and iii) to prevent decrements in indices of functional exercise recovery and immune function in subjects following a high-intensity resistance-training programme. According to results in a mechanistic rat model, these outcomes in humans could be prompted by modulating the oxidative stress and pro-inflammatory cytokine response, as well as through up-regulation of positive and down-regulation of negative myogenic factors. In an animal model of induced metabolic syndrome, which is characterized by chronic oxidative stress and low-grade inflammation, dietary TetraSOD® supplementation promoted endogenous antioxidant defence mechanisms in liver, modulated oxidative stress and inflammatory markers in plasma, and regulated genes involved in antioxidant, anti-inflammatory and immunomodulatory pathways in liver, adipose tissue, thymus, and spleen. Lastly, to date, there is no evidence that plant-derived SOD can be absorbed intact and bioactive. Elegant human muscle cell models have revealed a unique signaling effect of TetraSOD®, which may explain its observed antioxidant effects: inducing expression of the antioxidant response element known as NRF2, a nexus within the antioxidant network. The same study revealed an induction of primary antioxidant enzyme activities (SOD, GPX and CAT), which was further related to transcriptional up-regulation of a selected set of genes involved in response against oxidative stress, including NRF2 and HMOX1. *All scientific papers justifying the results here described are available upon request. Given TetraSOD®’s great stability, it can be used for most delivery systems. At the moment is being formulated for finished products used for applications to different health challenges which are affected by cellular oxidative stress. Another fundamental advantage of TetraSOD® is the very small daily dosage needed, with 25 mg for a full spectrum of health benefits from TetraSOD® supplementation. Ultimately, TetraSOD® is much more than just SOD. Contact: [email protected] Closed photobioreactors in land-based microalgae farm TetraSOD® is a novel, natural marine microalgae (Tetraselmis chuii; T. chuii)- derived bioactive that influences antioxidant, anti-inflammatory, hematologic, and metabolic/bioenergetic systems, as well as immune function.Theclosedphotobioreactor production system leverages patent pending, metabolism engineered growth conditions that are highly sustainable, honor the principles of green chemistry, and remove the need for bioengineering of this special strain, indigenous to the Spanish coast. Preclinical and clinical studies continue to reveal and validate its low dose yet potent, pleiotropic effects, impacting antioxidant response, body composition, muscular endurance, and carbohydrate metabolism/ glucose disposal. Microalgae comprise a biomass that has been the focus of numerous ingredient innovations e.g. Chlorella, Spirulina, and Haematococcus species. TetraSOD® is produced by harnessing the robust metabolic, “bioreactor” flexibility of a proprietary strain of T. chuii and cultured in cutting edge Photobioreactor technology, resulting in a complex powder that is concentrated in and standardized to antioxidant enzyme activity, including superoxide dismutase (SOD). TetraSOD® is at the vanguard of microalgae innovation in relation to human nutrition, forging sustainable green chemistry with a preclinical and clinical strategic research program, and expanding the palette of bioactivities and salutary effects. Fitoplancton Marino, S.L. is the company behind this unique ingredient, for more than 15 years one of the world’s leading marine microalgae producers. TetraSOD® is the most complete and comprehensive ingredient for the Healthy Ageing nutraceutical category but also offers athletes and individuals with active lifestyles an increased physiological response against oxidative stress to aid performance and recovery, all in a small, concentrated dose. SOD is the first essential enzyme in the antioxidant pathway, which makes it the first shield against oxidative stress; TetraSOD® is the most concentrated SOD source in the market, with science backed demonstrated efficiency on activating the antioxidant response pathway on human cells. A controlled, university-based human study in elite, young football players reported that daily supplementation with 25 mg of TetraSOD® elicited significantly greater and favorable changes in maximal endurance capacity and ergoespirometric values, body composition, blood markers of oxidative stress, and blood hemoglobin, unaccompanied by an increase in blood viscosity. TetraSOD®, a unique marine ingredient Jun22319

12 GHP International Life Sciences Awards 2022 Genomics has taken on new importance over the last few years, pushing forward our understanding of our bodies and how they work. The team at Genomnis was created primarily to simplify the genomics journey of its users, using the power of bioinformatics coupled with the experience of genetics experts.Their work has identified vital trends in data, earning them success in GHP’s International Life Sciences Awards 2022. We dig deeper to uncover more. Over the years, an enormous amount of data has been produced surrounding the field of genomics. The challenge, therefore, is to efficiently identify disease-causing mutations among millions of variations. In many ways, the aim is to find a needle in a haystack, but in the same way that there are better ways to find a needle than simply looking, the team at Genomnis have developed a solution which can predict the pathogenicity of mutations from any human gene. The team’s leading solution is known as the Human Splicing Finder system, and allows for the identification of splicing signals and the impact of mutations on these signals. With a host of different experiments currently underway in this specialist field, the Genomnis company can offer a unique perspective through its own range of services, designed specifically to overcome the challenges involved in handling so much data. Incredible ingenuity on the part of the Genomnis team has put them in the ideal position to develop innovative solutions for new challenges. A perfect example of their skill can be seen in the development of their Sequence Engineering solution, designed to optimise a sequence of interest to ensure its efficient cloning and processing in various organisms. In less than a minute, this impressive system can provide the ten best sequences from an almost infinite number of solutions. Analysing the world of human genetic data, and more broadly the development of drugs based on genetic information, is a rapidly growing field, but it is one which holds a great deal of importance to how we live. Most recently, this technology has been used in the development of so-called RNA vaccines for COVID-19. The use of the Sequence Engineering solution could analyse this information much more quickly, making it an invaluable addition to the drugs development pipeline. Despite the impressive team already in play, the Genomnis team are always looking to expand, drawing in highly skilled bioinformaticians and geneticists able to anticipate the evolution of the field to provide innovative systems in a timely manner. This determination to look to the future is one of the key factors that keeps the team ahead of the game. Being located in Marseille is a great benefit in this respect offering a nearby academic research unit as well as hospitals to see how their developments work in practice. The market is worldwide, but the development is always focused on local needs. Looking ahead, the Genomnis team are aiming to launch the Pro version of UMD-Predictor with access to the most recent human reference genome and increased accuracy, thereby increasing the difference with its competitors. The ability of the team to develop specific solutions that suit their customers’ needs has brought them enormous attention over the years. With drug development a constant in the background of our lives, it seems certain that businesses like Genomnis will become more important than ever before. Company: Genomnis SA Name: Pierre Béroud Email: [email protected] Web Address: Leading Pioneers in Genetic Bioinformatics 2022 Jun22416

13 GHP International Life Sciences Awards 2022 KAHLITY, founded in 2013, is a Swiss consultancy provider to the medical device, diagnostics and pharmaceutical industries with a team of strong dynamic consultants who have a proven track record for both managing projects and also providing consulting services to companies within the healthcare sector. KAHLITY has experience in the management of personnel in a multicultural and interdisciplinary environment, and by utilising their large network and many partnerships, the team is able to provide the best value for customers; often exceeding their expectations. Best Pharmaceutical & Medical Device Consultancy - Northwest Switzerland ince 2017, KAHLITY has been actively providing consulting services to companies specific to the European Medical Device Regulation 2017/745 (EU-MDR) and the European In-Vitro Diagnostics Regulation 2017/746 (EU-IVDR). KAHLITY has completed gap assessments between the European regulatory requirements and clients existing Quality Management System (QMS) or technical files/design dossiers, completed technical files remediation to those regulatory requirements, trained personnel on the regulatory framework, and worked with the clients to define what their upcoming regulatory strategy will be. The team’s expertise is specialised across medical devices including dental implants, orthopaedic implants, hearing aids, software, in-vitro diagnostics, drug device combination products, single-use devices, and both surgical and laboratory instruments (general, active implantable, implantable and in-vitro diagnostic). KAHLITY offers Swiss Authorised Representative services to manufacturers based outside of Switzerland, and KAHLITY France SAS offers European Authorised Representative services. KAHLITY’s team of consultants are experienced with industry gained skills, and motivated to deliver the clients expected outcome with frequent communication to the clients on progress. There is a flat structure within KAHLITY which means everyone works together to complete the endpoint. KAHLITY’s team members adapt themselves according to the best interest of clients, partners, and the company. When it comes to competitors, KAHLITY’s view point is positive and believes they become potential partners. The purpose of the healthcare industry is to contribute to providing a better life for people through the medicines, medical devices and pharmaceuticals products used on a routine basis. Therefore, KAHLITY believes in collaboration more than competition. KAHLITY collaborates with other consulting companies that are providing services that are similar or complementary to its own. The goal is to ensure their clients have all the resources they need at any time. KAHLITY’s headquarters are in Basel-City, Switzerland. Just a few minutes away from some of the largest medical device manufacturers in industry and with the added benefits of having an airport and two train stations, Basel provides the infrastructure so that the team can travel anywhere to meet and support clients. If there is a requirement to have a meeting room or a large conference room, fabulous offices are available to rent in Basel city centre. Ultimately, KAHLITY’s strength is its network of consultants, recruiters, and partners, which has been growing since its establishment, enabling it to offer the most personalised and flexible services to clients. With its strong structure and diverse skillset people, the aim for KAHLITY is to continue growing as a business so it can help its clients’ businesses do the same. Company: KAHLITY GmbH Contact: Mélodie Kahl Email: [email protected] Website: S Jun22587

14 GHP International Life Sciences Awards 2022 ISCA and it’s UK brand, Iscaguard, have become well known within the cosmetic preservative industry. With its roots leading back to 1998, ISCA boasts a wealth of experience, and as a result, its products provide exceptional results at an affordable cost. Best Cosmetic Chemical Manufacturer 2022 he genesis of ISCA’s story takes place 24 years ago, when the ISCA brand began to establish its reputation in the cosmetic preservatives by initially selling goods from several vendors. The company then chose to produce its own cosmetic preservative after identifying a gap in the industry. Through this decision, Iscaguard was born. 10 years down the line, Iscaguard ships to 39 nations and employs a workforce of 17 people, including two specialised microbiologists. Three core values support ISCA’s work – sustainability, openness, and honesty. These fundamental values act as a guide upon which ISCA has shaped the business, and as a result, have enabled ISCA to provide exceptional customer service. For example, ISCA is receptive to feedback from its users, employees, and stakeholders, and it truly values their transparency. It believes that through listening and taking on board such comments that it will become a better business. Further, it believes that through being honest itself, that it will maintain a sense of integrity. These traits are, therefore, embedded within the structure of Iscaguard. Consequently, Iscaguard has established a reputation as a skilled, adaptable, and trustworthy manufacturer of premium speciality chemical products that are also reasonably priced. The brand takes the time to pay attention to feedback and, on an important note, the trends emerging within the industry. Such elements, along with the backing of a vibrant team, have pushed Iscaguard to the forefront of the industry. Iscaguard’s technical team are constantly working to enhance existing formulations and are exploring new possibilities. This is greater supported by the team of microbiologists who are dedicated to conducting a thorough testing service, providing clients with a range of testing alternatives, and are persistently searching for new or enhanced testing techniques. The newest branch, ISCA Cosmetic Testing, is composed of a competent team of women in science. ISCA Cosmetic Testing takes the confusion out of cosmetic product testing. However, whilst the brand has achieved unprecedented levels of success, it has also faced its fair share of challenges – Gemma Jones, Head of Cosmetic Microbiology, explains: ‘COVID-19 had a significant impact on the trends seen in the cosmetics market. There was a lesser demand for makeup products like lipsticks and foundations, and an increased demand for at home skin care treatments. More significantly, there was a major demand for antibacterial formulations and hygiene products, and consumers were panic buying. As a result, in 2020 we saw an increase in our preservative sales. By 2021 however, we were in the same position as many other companies. R&D work across the globe had ceased and so no new products were being developed and demand dropped. Additionally, with the effect on global logistics, we saw a sharp increase in raw material prices and freight costs. Now in 2022 we are starting to see the effects of COVID-19 slowly dissipating as R&D work has been able to resume.’ Indeed, as the industry enters a period of recovery, Iscaguard has plans to further improve upon its services. It endeavours to utilise the lessons that it has learnt throughout the pandemic to cater to a new, broader clientele through developing its services and growing its range of award-winning and eco-certified formulations. Furthermore, Iscaguard vows to continue putting its clients first, as this is the company’s purpose. Contact: Gemma Jones Company: ISCA Web Address: T Jun22663

15 GHP International Life Sciences Awards 2022 Seafood issuchan important part of somany people’s lifestyles, but the team at Umami Meats know that many fishes have become near extinct because of industrial fishing practices. They want people to have their fish, and eat it too, through cultivated, ‘not caught’ seafood that is better for everyone. In GHP’s International Life Sciences Awards 2022, the team were rewarded for their incredible efforts. We caught up with Mihir Pershad to uncover how they’ve managed to achieve such astonishing results. Humanity’s impact on the planet has become clearer than ever before over the last few years. The work of the team from Umami Meats has been directed at developing pioneering solutions to the various difficulties facing the world as a whole, focusing primarily on the seafood market. Their delicious, nutritious, and affordably cultivated fish could revolutionise the way in which we eat – but how have they done it? The world of alternative protein has grown dramatically over the last few years, with overfishing causing significant gaps in our ability to feed populations using traditional production methods. “Industrial animal agriculture and aquaculture increase the risk of zoonotic diseases, damage our environment, and are a leading cause of species extinctions,” Mihir explains. “As we are building on the frontier of the life sciences sector, we are always looking at the newest advances to help us achieve our goal of cultivating seafood at price parity with traditional caught fish.” The development of this technology in Singapore is by no means surprising. It is, in many ways, the ideal location from which to launch a game-changing technology. As a trading and business hub for Southeast Asia and the first country in the world to approve sale of cultivated meat, it sets the standard for others. “Singapore is building a regional food-tech center and investing resources to support companies that are developing novel food production technologies that enable localized, climate resilient food supply,” Mihir informs us. It’s one of the reasons why the business has not only been able to establish itself, but to take the industry by storm. The ability to cultivate meat and fish is an incredibly important issue that must be overcome in the near future. To combat the impressive challenges, an incredible team has been assembled by Umami Meats. “We are assembling a deeply technical team with experience in fish cell line development, muscle and fat tissue maturation, bioprocess engineering, and culinary science,” Mihir tells us. “Our ideal team members are inquisitive, independent thinkers who love solving difficult problems and thinking of novel approaches to long-established challenges. We encourage our team members to take smart risks and explore new approaches and give them the resources and freedom to do so.” Such an innovative approach to an age-old problem has not been easy to come by, but the team have never settled at any point. Mihir was proud to tell us a little more about some of the projects that the Umami Meats team have been working on: “We are going to be launching a number of product demonstrations and prototypes over the next 6-8 months, showcasing increasingly structured, premium seafood products from a range of IUCN listed species. We are also establishing additional collaborations to begin the scale up of our technology and plan to announce some of these in the coming months.” With such amazing plans on the horizon for this talented team, we’ve little doubt they will achieve incredible results in the future. The world of alternative protein has gained a new champion in the form of Umami Meats. We cannot wait to see what they do next. Company: Umami Meats Name: Mihir Pershad Email: [email protected] Web Address: Best Aquaculture Company - Asia Jul22142

16 GHP International Life Sciences Awards 2022 iRhythm Technologies’ work helps save lives. It has created an innovative service – Zio XT – which optimises and transforms the data it collects into clinically actionable information.The service was designed with the aim to improve the detection of cardiac arrythmias and, in turn, help clinicians make a faster and more accurate diagnosis. The way in which cardiac arrhythmias are diagnosed is being redefined. Digital healthcare company iRhythm Technologies Ltd has brought forth an innovative service – Zio XT. With the help of a propriety AI algorithm, Zio combines a patented wearable biosensor with AI based data analytics to transform data from millions of heartbeats into clinically actionable information. The device has been designed with patients in mind, and as a result, it can be worn continuously for up to 14 days whilst minimising disruption to patients’ daily activities. iRhythm Technologies was founded with the objective to improve arrythmia detection on a global scale, and consequently, the company believes that data quality and quantity has the potential to alter clinical management of patients. Moreover, iRhythm Technologies works in collaboration with healthcare teams and hospital systems to enhance workflows and decrease inefficiencies. As a result of iRhythm Technologies’ exceptional efforts, clinical professionals can now identify and diagnose patients more quickly and precisely than ever before. Zio XT was designed to maximise quality data collection, giving clinicians a fuller picture of their patients’ heart rhythm, while disruption to daily activities have been kept to a significant low. Research undertaken by iRhythm has found that 98% of patients comply with the prescribed wear time1, and in a direct head to head patients preferred wearing Zio for 14 days rather a Holter for only 24 hours2. 99% of clinicians agree with the finding in the Zio report1, providing clinicians with a trusted solution to help diagnose accurately the first time of monitoring. Indeed, iRhythm Technologies prides itself on its drive for progress – it is constantly striving to innovate and improve. It entered the UK market in 2016 after a great amount of success in the US. Tash Brown, UK Product Marketing Manager, explains, ‘2014 research conducted by the British Heart Foundation found that 5,145 people aged between 45-54 died as a result of cardiovascular disease a year, in comparison to 4,954 from the same age bracket in 2012. As a company, we knew we had a solution that solved an unmet need in the NHS, and we continue to make strides towards reducing the devastating impact that cardiovascular disease can have.’ Of course, this makes the company enormously unique. It has been repeatedly recognised for its contributions to the healthcare field, especially by the Accelerated Access Collaborate (AAC) as part of the NHS AI Lab with the National Institute for Health Research. In 2020, it was awarded the Artificial Intelligence in Health and Care Award by the aforementioned organisations, which then provided iRhythm Technologies with funding to evaluate Zio XT for real world clinical, operational, and financial benefits at selected NHS trusts. However, as these evaluations are drawing to a close, iRhythm Technologies is facing a new challenge; how will the NHS fund and support the implementation of Zio XT system wide? Tash discloses, ‘initial outcomes from implementing Zio at scale have been hugely positive, so we are working closely with trusts to showcase the “value” our service brings across a patient pathway, creating a long-term sustainable service in the NHS. As hospital systems look to procure proven innovations through valuebased mechanisms rather than just “cost”, we are partnering with stakeholders to navigate the changing NHS landscape.’ iRhythm Technologies’ benefits have been widely documented, including in the case of one patient, who was fitted with the device as part of the NHSX AI in Health and Care Award. On the 10th day of recording, the patient’s heart stopped beating for 28 seconds whilst they slept. The data was reviewed by one of iRhythm’s highly specialised cardiac physiologists and the patient’s clinician was notified. The patient was brought in to the hospital where they were fitted with a pacemaker and the condition was treated effectively. Holter monitoring typically only take places over a 24 or 48-hour time period. This is, in turn, a primary example as to how longer term monitoring with iRhythm Technologies’ Zio XT can – and does – help save lives. As such, the company’s plans involve the continued support of patients and staff throughout the NHS, and it hopes that its work won’t only be seen as a case study, but also as a catalyst for long term commissioning throughout the NHS framework. Contact: Tash Brown Company: iRhythm Technologies Ltd Web Address: Best Ambulatory Cardiac Monitoring Solution 2022: Zio® by iRhythm Jul22144 1) Data on file, iRhythm Technologies, 2019 2) Barrett, et al., Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring. American Journal of Medicine, 2014.

17 GHP International Life Sciences Awards 2022 With more than 30 years’ experience in serving life science leaders, Azzur Group LLC has developed and tailored solutions specifically to address the unique challenges of earlyphase manufacturers and accelerate their speed to market. With Azzur Group focusing on compliance, this means its clients can focus on what they do best: the science. Most Innovative Early-Phase Biotech Manufacturing Solutions Provider 2022 rom Discovery to Delivery™, Azzur Group provides the life science community with full lifecycle solutions for all their GxP needs. From Azzur Cleanrooms on Demand™ facilities, to its labs, training centres, and consulting offices across the nation, Azzur Group helps organisations start, scale, and sustain their growing enterprises. With over three decades of service to the life science community, it has become a trusted partner to the world’s leading pharmaceutical, biotechnology, medical device, and healthcare companies, as well as their supply chain. Playing a key part in Azzur Group’s success are its mission and core values, which its team take pride in. The mission is simple: to lead the healthcare and life science industries in innovative quality and compliance solutions, From Discovery to Delivery™. And its values have stayed the same since it was first established, remaining the catalyst to its success. As the industry evolves, Azzur Group will remain agile while staying true to its fundamental values. These are putting others first; having courage to take action; taking personal responsibility; and, having fun. Azzur Group likes to think of itself as proactive rather than reactive. For instance, Azzur Cleanrooms on Demand™ was developed to support its fast-moving and entrepreneurial clients looking for a middle ground between building their own facilities and outsourcing to contract development and management organisations (CDMOs/CMOs). In 2015 and 2016, the company took action after receiving repeat requests from its clients asking for the design and build of cleanrooms in high rises that were unsuitable for GMP manufacturing. Last year, Azzur Group opened a new facility in Burlington, MA, which was already at capacity before even opening its doors. It is continuing to open additional facilities in the coming year around pharma and biotech hubs in Raleigh, NC; San Francisco, CA; and Devens, MA. In doing so, it will continue to support life science organisations with their cGMP needs, allowing them to accelerate the development of life-changing pharmaceuticals and therapeutics. With the company being based across the entire United States, there are many benefits for pharmaceutical and biotech companies. Azzur Cleanrooms on Demand™ operations have been purposely set up in areas with thriving or emerging biotech and life science industries. Its future growth will continue to serve burgeoning life science hubs across the country. With each Cleanrooms on Demand™, Azzur Group creates new employment opportunities in the region. For example, its operation in Vista, CA has created 20 new, highly specialised jobs in the first year alone. It also enables life science companies in those regions to rapidly move from scientific discoveries to manufacturing and delivery of treatments, therapies, and other advances. With that success comes the opportunity for clients to expand their workforces, as well. Azzur Group is forward-looking, and it stays on the path that best benefits its clients’ needs. The difference between Azzur Group and its competitors is that it offers its clients a variety of wraparound services in good manufacturing practices, regulatory and quality advisory services, materials handling and storage, as well as full-scale laboratory services and GxP training. Most companies do not do that. And none of what Azzur Group does could be possible without its multidisciplinary team and their comprehensive approach to client challenges. Many of the company’s employees have practical life sciences career experience, while others have advanced degrees related to life sciences. Still, others have a background in engineering. These academic and practical attributes contribute to a company culture that supports its clients and enables the company to act as a trusted advisor to its fast-moving client base. Azzur Group is proud to be Certified™ by Great Place to Work®, based entirely on what its current employees say about working at the company. Its main driver for this success is how it continues to meet its mission and core values head-on. Throughout 2022 and looking into 2023, Azzur continues to scale operations throughout the United States, breaking ground in pharmaceutical and biotech hubs—bringing an additional 70+ cleanrooms to innovators throughout the country. Company: Azzur Group LLC Contact: Katie Kiley Brown Email: [email protected] Website: F Jul22554 Azzur Group LLC